Showing results (11-20 of 56) with videos related to
Sort By:
Pageof 6
European Journal of Neurology|July 15, 2016
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal studyB Nourbakhsh, L Julian, E WaubantMultiple Sclerosis (Houndmills, Basingstoke, England)|January 18, 2012
Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherenceG Giovannoni, E Southam, E WaubantJournal of Neurology, Neurosurgery, and Psychiatry|January 29, 2008
Predictors of the location of multiple sclerosis relapseS Deen, P Bacchetti, A High, et al.Clinical Neuropathology|January 1, 1987
Etiology of pituitary apoplexy: review and case presentationR W Leech, D Goodkin, G Obert, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|March 29, 2014
Composite end points to assess delay of disability progression by MS treatmentsJ Zhang, E Waubant, G Cutter, et al.Neuroradiology|May 1, 1997
MRI of intramedullary sarcoidosis: follow-up of a caseE Waubant, C Manelfe, A Bonafé, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 17, 2008
Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosisA Gajofatto, P Bacchetti, B Grimes, et al.Neurology|September 17, 1999
A pilot study of MRI activity before and during interferon beta-1a therapyE Waubant, D E Goodkin, R Sloan, et al.Neurology|September 13, 2006
Are initial demyelinating event recovery and time to second event under differential control?T West, M Wyatt, A High, et al.Archives of Neurology|September 17, 1999
Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disabilityP B Andersson, E Waubant, L Gee, et al.Pageof 6